Evidence map›Paper›PMID 42447806›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

IL7R depletion mitigates neuroinflammation and ischemic stroke via AKT dephosphorylation dependent LCP1 suppression in mice.

Qianqian Yin, Shaomeng Chen, Decao Yang, Ruoxi Li, Hang Hang, Chan Xu, Xiaoyue Wang, Jinxin Li, Jingyi Zhao, Jianing Wang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Qianqian YinInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China; Biobank, Peking University Third Hospital, Beijing, China.
Shaomeng ChenInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Decao YangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Ruoxi LiInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China; Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.
Hang HangBeijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.
Chan XuBeijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.
Xiaoyue WangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Jinxin LiInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Jingyi ZhaoInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Jianing WangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Jiaxin ChenInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Panxi SunInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Tingting ZhangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Qianxue HuInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Jiaxing XuInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China.
Lixiang XueInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China; Biobank, Peking University Third Hospital, Beijing, China.
Cuiying LiuBeijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.
Sheng HuangDepartment of Ophthalmology, Tongren People's Hospital, Tongren, Guizhou Province, China.
Heng ZhaoBeijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China; Department of Neurology, Tongren People's Hospital, Tongren, Guizhou Province, China. Electronic address: heng.zhao10@gmail.com.
Yan WangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China; Medical Research Center, Peking University Third Hospital, Beijing, China. Electronic address: yanwang2019@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke remains a leading cause of death and long-term disability worldwide. After reperfusion following ischemic stroke, peripheral immune cells infiltrate the injured brain hemisphere and exacerbate secondary damage. Among these cells, monocytes are among the predominant population. In this study, we performed single-cell RNA sequencing of immune cells isolated from the brain 72 h after infarction and characterized the heterogeneity of brain infiltrating monocyte-derived macrophages. We identified an IL7R

Indexed as

Ischemic StrokeNeuroinflammatory DiseasesProto-Oncogene Proteins c-aktReceptors, Interleukin-7AnimalsMacrophagesMaleMiceMice, Inbred C57BLPhosphorylationProto-Oncogene Proteins c-aktReceptors, Interleukin-7IL7RIschemic strokeLCP1Lipid metabolismMonocytes derived macrophages (MoDMs)

Identifiers

PMID42447806
PMCPMC13382582

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.